Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/19960
Full metadata record
DC FieldValueLanguage
dc.contributor.authorParajuli, R-
dc.contributor.authorMedhi, C-
dc.date.accessioned2013-07-22T08:16:11Z-
dc.date.available2013-07-22T08:16:11Z-
dc.date.issued2006-01-
dc.identifier.issn0975-0975(Online); 0376-4710(Print)-
dc.identifier.urihttp://hdl.handle.net/123456789/19960-
dc.description146-158en_US
dc.description.abstractThe anticancer drug, 9-substituted acridine-4-carboxamide, intercalates with sequences in nucleic acids. Some analogues of this drug with substituents at 9-position are chosen for studying the intercalative abilities with Watson Crick base pairs, AT, TA, GC and CG. Ab-initio HF/6-3l G** and B3LYP methods are used for calculating interaction energies of drug-sequence complexes and the sequence specificity of drugs are analysed from the interaction energies. The computed interaction energies of various drugs with CG and GC sequences are significantly lower than those of others. Hence, these drugs acquire high specificity for GC and CG sequences. Moreover, stacking interaction of heavy atoms present in sequence and drug stabilizes the optimum structures.en_US
dc.language.isoen_USen_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceIJC-A Vol.45A(01) [January 2006]en_US
dc.titleMonitoring the sequence specific intercalation in nucleic acids by 9-substituted acridine-4-carboxamidesen_US
dc.typeArticleen_US
Appears in Collections: IJC-A Vol.45A(01) [January 2006]

Files in This Item:
File Description SizeFormat 
IJCA 45A(1) 146-158.pdf2.24 MBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.